A drug-resistant superbug fungus has infected nearly 7,000 Americans in 2025, evading treatments and threatening vulnerable patients in hospitals nationwide.
Story Snapshot
- Candida auris cases hit at least 7,000 in 2025, nearing last year’s record of over 7,500, with over half of the states affected.
- The fungus is resistant to all common antifungal drugs, leaving infected patients without effective treatments in healthcare settings.
- It spreads via catheters, breathing tubes, and IVs, and can survive for long periods on hospital and nursing home surfaces.
- Mortality rates reach 30-60% among patients, many of whom are already seriously ill, with a recent study showing over half needing ICU care.
Candida Auris Spread Accelerates in 2025
Centers for Disease Control and Prevention data show Candida auris infected at least 7,000 people across U.S. medical facilities in 2025. Hospitals and nursing homes struggle to contain the fungus, first reported in the U.S. in 2016. Cases surged rapidly in recent years, with more than half of the states reporting clinical infections this year.
One week from year-end, totals approach the prior record of over 7,500 cases. The pathogen persists on surfaces, infecting patients through medical devices like catheters and IVs.
Rapidly spreading fungus already in California, 27 other states presents ‘urgent’ threat, CDC warns https://t.co/WlkosqT89M
— KTLA (@KTLA) March 21, 2023
Superbug Resists All Standard Treatments
Certain Candida auris strains qualify as superbugs because they are resistant to all standard antifungal medications. Healthy individuals often fight off infections naturally, but vulnerable hospital patients face lethal risks.
Melissa Nolan, assistant professor of epidemiology at the University of South Carolina, warned that resistant cases offer no viable treatments, leaving patients to combat the pathogen alone. This resistance hampers containment efforts, allowing unchecked spread in healthcare environments where patients are already compromised.
A July 2025 study on cases mainly in Nevada and Florida revealed severe impacts. Over half of the patients required admission to the intensive care unit.
More than one-third needed mechanical ventilation. Patients, averaging 60-64 years old, saw over half requiring blood transfusions. These findings underscore the fungus’s danger to older, frail Americans reliant on medical care.
Climate Adaptation Raises Long-Term Alarms
Johns Hopkins microbiologist Arturo Casadevall explained that human body temperature historically deterred environmental fungi. Rising global temperatures may enable fungi such as Candida auris to adapt, breaching the “temperature barrier” that protects human survival.
The CDC previously estimated 30-60% mortality in limited patient data, though many had complicating serious illnesses. Facilities must enhance sterilization and monitoring to protect patients amid this evolving threat.
Under President Trump’s leadership, a renewed focus on American health priorities could address such crises. Past administration efforts to make America healthy again highlight opportunities to strengthen defenses against emerging pathogens and prioritize citizen safety over bureaucratic delays.
